Directory
>
Scott Vafai
Scott Vafai
Vice President, Translational Medicine | Verve Therapeutics
Boston, Massachusetts, United States
Scott Vafai
Summary
Scott Vafai is a physician-scientist with a robust background in translational medicine and clinical development, currently serving as Vice President of Translational Medicine at Verve Therapeutics. With a unique blend of clinical and scientific training, he specializes in advancing innovative therapies from discovery to clinical trials, particularly in gene editing and therapy. His extensive experience includes leading clinical trial oversight, regulatory strategy, and biomarker strategy. Scott has co-founded a medical technology company and holds multiple patents in the field. He has directed teams at prestigious institutions like the Broad Institute and has a strong publication record in mitochondrial biology and metabolic disorders. His diverse expertise spans biochemistry to clinical pharmacology, making him a key player in the life sciences sector. Scott's commitment to improving patient outcomes is evident in his work on diabetes and other chronic diseases.
Scott Vafai
Work Experience
Vice President, Translational Medicine at
Verve Therapeutics
October 2021 - Present
Co-Founder at
Metavention, Inc.
January 2012 - Present
Executive Director, Translational Medicine at
Verve Therapeutics
September 2020 - October 2021
Senior Director, Translational Medicine and Clinical Pharmacology at
Sanofi
June 2020 - September 2020
Director, Translational Medicine and Clinical Pharmacology at
Sanofi
January 2018 - May 2020
Director, Mitochondrial Therapeutics Accelerator at
Broad Institute of MIT and Harvard
January 2015 - January 2018
Instructor in Medicine at
Harvard Medical School
July 2013 - June 2016
Instructor in Medicine at
Massachusetts General Hospital
July 2013 - June 2016
Endocrinology Fellow at
Massachusetts General Hospital
June 2009 - July 2013
Research Fellow at
Massachusetts General Hospital
July 2009 - June 2013
Medical Residency at
Brigham and Women's Hospital
July 2007 - July 2009
Scott Vafai
Education
January 2002 - January 2007
January 1998 - January 2002
Rutgers Preparatory School
January 1985 - January 1998
Frequently Asked Questions about Scott Vafai
What is Scott Vafai email address?
Scott Vafai's primary email address is ******@vervetx.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Scott Vafai work for?
Scott Vafai is a Vice President, Translational Medicine at Verve Therapeutics, a company specializing in Drugs, proprietaries, & sundries.
Where Scott Vafai graduated from?
Scott Vafai holds a degree in Medicine from Harvard Medical School.
How can I directly contact Scott Vafai?
To contact Scott Vafai directly, you can use the email address ******@vervetx.com. Complete contact information is available upon registration with Muraena.
Who is Scott Vafai?
Scott Vafai is a physician-scientist with a robust background in translational medicine and clinical development, currently serving as Vice President of Translational Medicine at Verve Therapeutics. With a unique blend of clinical and scientific training, he specializes in advancing innovative therapies from discovery to clinical trials, particularly in gene editing and therapy. His extensive experience includes leading clinical trial oversight, regulatory strategy, and biomarker strategy. Scott has co-founded a medical technology company and holds multiple patents in the field. He has directed teams at prestigious institutions like the Broad Institute and has a strong publication record in mitochondrial biology and metabolic disorders. His diverse expertise spans biochemistry to clinical pharmacology, making him a key player in the life sciences sector. Scott's commitment to improving patient outcomes is evident in his work on diabetes and other chronic diseases.
Scott`s contact details
******@vervetx.com
Colleagues
Executive Director, External Manufacturing
Senior Vice President Regulatory Affairs
Vice President, Editing Development
Senior Vice President, Chemistry
Senior Vice President, Investor Relations and Corporate Communications